Nature Search

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

CAR T cells targeting PSMA and engineered to be resistant to immunosuppressive TGFβ signaling exhibit dose-dependent toxicity and expansion following infusion, with some transient antitumor activity, in patients with metastatic castration-resistant prostate cancer

Vivek Narayan
Julie S. Barber-Rotenberg
Naomi B. Haas
Research21 Mar 2022
Nature Medicine

Volume: 28, P: 724-734
Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells

Infusion of CD19-directed chimeric antigen receptor T cells into two patients with chronic lymphocytic leukaemia resulted in complete tumour remission and persistence of the infused cells more than ten years later.

J. Joseph Melenhorst
Gregory M. Chen
Carl H. June
Research02 Feb 2022
Nature

Volume: 602, P: 503-509
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Genetically engineered T cells that induced remission in a patient with chronic lymphocytic leukaemia were found to have disruption of the TET2 gene, which caused T cell changes that potentiated their anti-tumour effects.

Joseph A. Fraietta
Christopher L. Nobles
J. Joseph Melenhorst
Research30 May 2018
Nature

Volume: 558, P: 307-312
Author Correction: Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells

J. Joseph Melenhorst
Gregory M. Chen
Carl H. June
Amendments and Corrections07 Dec 2022
Nature

Volume: 612, P: E22
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

A CAR gene unintentionally introduced in a contaminating leukemia cell during the manufacturing of CAR T cells caused a patient to relapse after therapy.

Marco Ruella
Jun Xu
J. Joseph Melenhorst
Research01 Oct 2018
Nature Medicine

Volume: 24, P: 1499-1503
A quantitative approach for measuring the reservoir of latent HIV-1 proviruses

An assay to measure the latent HIV-1 reservoir that separately quantifies intact and defective proviruses will facilitate evaluation of HIV-1 cure strategies by measuring the provirues that pose a barrier to cure.

Katherine M. Bruner
Zheng Wang
Robert F. Siliciano
Research30 Jan 2019
Nature

Volume: 566, P: 120-125
Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Rajiv V. Dave
Baek Kim
Zaid Al-Ishaq
ResearchOpen Access25 Mar 2021
British Journal of Cancer

Volume: 124, P: 1785-1794

Search

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Author Correction: Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

A quantitative approach for measuring the reservoir of latent HIV-1 proviruses

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Search

Quick links

Search

Filter By:

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

A quantitative approach for measuring the reservoir of latent HIV-1 proviruses

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Search

Quick links

Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells

Author Correction: Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells